Historical daily share price chart and data for Johnson & Johnson since 1970 adjusted for splits and dividends. The latest closing stock price for Johnson & Johnson as of September 12, 2024 is 164.64.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Johnson & Johnson Historical Annual Stock Price Data | ||||||
---|---|---|---|---|---|---|
Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
2024 | 153.1815 | 156.2831 | 167.3800 | 142.1935 | 164.6400 | 7.52% |
2023 | 154.1798 | 169.0029 | 170.9567 | 141.1240 | 153.1275 | -8.60% |
2022 | 161.4853 | 158.5414 | 173.0304 | 147.1051 | 167.5423 | 5.97% |
2021 | 150.9818 | 141.0724 | 163.7992 | 138.8414 | 158.1070 | 11.45% |
2020 | 129.6185 | 128.0659 | 141.8656 | 98.1429 | 141.8656 | 10.85% |
2019 | 117.2338 | 109.8277 | 128.4782 | 108.0825 | 127.9782 | 15.35% |
2018 | 112.7947 | 116.5416 | 127.0992 | 101.3239 | 110.9453 | -5.14% |
2017 | 107.2495 | 94.5232 | 119.6052 | 91.1940 | 116.9518 | 24.40% |
2016 | 91.4542 | 79.7409 | 100.9459 | 75.9872 | 94.0092 | 15.32% |
2015 | 77.9765 | 80.5469 | 83.5264 | 71.4802 | 81.5186 | 1.16% |
2014 | 76.6643 | 68.2597 | 83.6294 | 64.9528 | 80.5854 | 17.34% |
2013 | 63.3900 | 51.5578 | 71.7090 | 51.4850 | 68.6796 | 34.62% |
2012 | 47.8373 | 46.2460 | 52.3217 | 44.1744 | 51.0192 | 10.83% |
2011 | 43.7903 | 42.5487 | 46.8234 | 39.4074 | 46.0354 | 9.89% |
2010 | 41.3280 | 42.3136 | 43.5285 | 37.9328 | 41.8917 | -0.58% |
2009 | 37.2056 | 38.3861 | 42.4968 | 29.7419 | 42.1370 | 11.28% |
2008 | 40.4787 | 40.5703 | 45.3513 | 35.0190 | 37.8671 | -7.77% |
2007 | 38.8677 | 39.8542 | 42.1030 | 36.2234 | 41.0566 | 3.61% |
2006 | 36.9000 | 36.1378 | 41.2400 | 33.3056 | 39.6262 | 12.44% |
2005 | 37.5446 | 36.1660 | 40.0741 | 35.2055 | 35.2406 | -3.36% |
2004 | 31.8392 | 29.1332 | 36.6605 | 28.0378 | 36.4650 | 25.17% |
2003 | 29.3963 | 30.6602 | 32.6409 | 27.3549 | 29.1332 | -2.11% |
2002 | 31.7154 | 32.0893 | 35.9136 | 23.0264 | 29.7625 | -7.88% |
2001 | 28.2157 | 27.5118 | 33.3302 | 22.5308 | 32.3080 | 13.97% |
2000 | 23.9642 | 24.5746 | 28.3480 | 18.3257 | 28.3480 | 14.04% |
1999 | 24.9326 | 21.7896 | 28.2825 | 20.2902 | 24.8571 | 12.46% |
1998 | 19.6514 | 16.9228 | 23.4523 | 16.6471 | 22.1032 | 28.99% |
1997 | 15.4123 | 12.7587 | 17.4118 | 12.7587 | 17.1361 | 34.31% |
1996 | 12.3546 | 10.6445 | 13.7845 | 10.6445 | 12.7587 | 18.11% |
1995 | 8.6262 | 6.7569 | 11.5605 | 6.6639 | 10.8024 | 59.14% |
1994 | 5.6677 | 5.4753 | 6.8970 | 4.4746 | 6.7879 | 25.00% |
1993 | 5.0197 | 5.8451 | 5.8451 | 4.2853 | 5.4305 | -8.93% |
1992 | 5.7755 | 6.5091 | 6.7486 | 5.0454 | 5.9632 | -10.19% |
1991 | 5.1571 | 3.9901 | 6.6975 | 3.7404 | 6.6395 | 62.34% |
1990 | 3.5475 | 3.3426 | 4.1408 | 2.9027 | 4.0898 | 23.38% |
1989 | 2.7654 | 2.2830 | 3.3147 | 2.2830 | 3.3147 | 42.64% |
1988 | 2.1835 | 2.0808 | 2.3910 | 1.8742 | 2.3239 | 16.52% |
1987 | 2.2793 | 1.7687 | 2.7717 | 1.7088 | 1.9945 | 15.79% |
1986 | 1.6560 | 1.3328 | 1.9293 | 1.2267 | 1.7225 | 27.42% |
1985 | 1.1292 | 0.8896 | 1.4065 | 0.8771 | 1.3518 | 49.85% |
1984 | 0.8408 | 0.9862 | 1.0224 | 0.6930 | 0.9021 | -8.53% |
1983 | 1.0882 | 1.1665 | 1.2055 | 0.9469 | 0.9862 | -15.66% |
1982 | 0.9518 | 0.8424 | 1.2019 | 0.7520 | 1.1693 | 36.94% |
1981 | 0.7757 | 0.7465 | 0.8738 | 0.6514 | 0.8539 | 14.54% |
1980 | 0.5854 | 0.5579 | 0.7474 | 0.4867 | 0.7455 | 29.40% |
1979 | 0.5169 | 0.5250 | 0.5815 | 0.4673 | 0.5761 | 10.49% |
1978 | 0.5370 | 0.5187 | 0.6239 | 0.4584 | 0.5214 | -1.77% |
1977 | 0.4818 | 0.5294 | 0.5308 | 0.4267 | 0.5308 | 0.42% |
1976 | 0.5815 | 0.6033 | 0.6443 | 0.4879 | 0.5286 | -12.02% |
1975 | 0.5929 | 0.5505 | 0.6598 | 0.4891 | 0.6008 | 12.01% |
1974 | 0.6507 | 0.7354 | 0.7846 | 0.4970 | 0.5364 | -27.71% |
1973 | 0.7805 | 0.8418 | 0.8549 | 0.6877 | 0.7420 | -13.21% |
1972 | 0.7713 | 0.6380 | 0.8649 | 0.6192 | 0.8549 | 32.98% |
1971 | 0.5543 | 0.3717 | 0.6453 | 0.3717 | 0.6429 | 73.71% |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Medical | Large Cap Pharmaceutical | $396.762B | $85.159B |
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. |
Stock Name | Country | Market Cap | PE Ratio |
---|---|---|---|
Eli Lilly (LLY) | United States | $875.238B | 101.31 |
Novo Nordisk (NVO) | Denmark | $606.849B | 46.31 |
AbbVie (ABBV) | United States | $343.713B | 18.19 |
Merck (MRK) | United States | $290.538B | 17.62 |
AstraZeneca (AZN) | United Kingdom | $249.688B | 22.25 |
Novartis AG (NVS) | Switzerland | $235.632B | 16.38 |
Pfizer (PFE) | United States | $168.074B | 21.97 |
Sanofi (SNY) | $145.530B | 13.78 | |
Innoviva (INVA) | United States | $1.214B | 6.74 |